Vol. 18/ No. 20

Researchers are seeking to determine whether the plethora of new therapies that have been introduced in recent years in the advanced and metastatic settings can benefit patients at risk of recurrence earlier in the treatment timeline for melanoma.

A new generation of more selective inhibitors of CDK4 and CDK6 has entered the clinic in combination therapies for patients with breast cancer. These agents also are being investigated in patients with KRAS-mutant malignancies.

Paul A. Bunn Jr, MD, discusses strategies for analyzing and responding to signs of progression for patients receiving immunotherapy for non-small cell lung cancer.

Tazemetostat, a small molecule that targets epigenetic activity of the EZH2 gene, is being investigated as a treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma.

The landscape for treating patients with gastroesophageal cancers is undergoing rapid change, and international cooperation among specialists is crucial to the advancement of care.

Although surgery and radiotherapy are standard treatment modalities for grade T1/T2 oral cavity cancer, both approaches have well-documented limitations, including their association with adverse effects that lower quality of life for patients.

There are many elegant examples of basic laboratory research or mathematical modeling studies that resulted, through the conduct of clinical trials, in major paradigm changes in how cancer is managed.

It was just 6 years ago that options for patients with metastatic melanoma began to expand. In 2011, the approval of ipilimumab (Yervoy), the pioneering checkpoint immunotherapy for patients with unresectable or metastatic disease, marked the first milestone.